Halozyme Therapeutics, Inc. · NASDAQ:HALO

Halozyme Therapeutics — Q4 2020 Earnings Presentation

13 slides from Halozyme Therapeutics's earnings presentation, Feb 23, 2021

  1. Slide 1: Fourth Quarter and Full Year 2020 Financial Results Presentation

    Fourth Quarter and Full Year 2020 Financial Results Presentation February 23, 2021

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements In addition to historical information, the statements set forth in this presentation include forward-looking statements including, without limitation, statements concerning the Company’s expected future financial performance (including the Company's financial outlook for 2

  3. Slide 3: Return to Royalty Growth Primarily Driven by DARZALEX SC Launch

    Return to Royalty Growth Primarily Driven by DARZALEX® (daratumumab) SC Launch Quarterly Royalty Revenue ($M) Annual Royalty Revenue ($M) 86% year-over-year growth and 34% sequential growth in Q4 2020 driven by DARZALEX® SC utilizing ENHANZE® 32.0 23.9 89 17.2 16.8 70 15.8 Q4 Q1 Q2 Q3 Q4 2019 2020 2

  4. Slide 4: Five Products Commercialized in Global Markets: Wave 1 and 2 Launches

    Five Products Commercialized in Global Markets: Wave 1 and 2 Launches Wave 1 / / Wave 2 / DARZALEX® SC 4

  5. Slide 5: 16 Products In Development by YE 2021; Five New Products Expected to Enter Clinic

    Project 16 Products In Development by YE 2021 Phase 1 Phase 1 Phase 2 Phase 3 Current Program / Product Indications New Starts Ongoing Trial Starts Trial Starts ARGX-117 (argenx) Multifocal motor neuropathy Anti-TIM3 (BMS) Solid tumors Amivantamab (Janssen) Solid tumors CAP256V2LS (CAPRISA) HIV (vac

  6. Slide 6: Projected Milestones Drive Revenue and Free Cash Flow

    Projected Milestones Drive Revenue and Free Cash Flow 3 Year Forward Milestone Revenue Projection 2019 2020 2021 2022 2023 End 2018 $225 - $300M Projection Actual: $183M End 2019 $350 - $450M Updated Projection Actual: $123M End 2020 $400 - $450M Projection Includes development, commercial and new a

  7. Slide 7: Continue to Return Significant Capital to Shareholders

    Continue to Return Significant Capital to Shareholders Capital Allocation Priorities 1 Maintain Strong Balance Sheet 2 Share Repurchases 3 Internal and External Growth • Cash & cash • $550M program • Continue to fund equivalents $368.0M 2019-2022 ENHANZE® – $350M completed to at YE 2020 date at an a

  8. Slide 8: Fourth Quarter 2020 Revenue Highlights

    Fourth Quarter 2020 Revenue Highlights1 $ U.S. in Millions (unaudited) 4Q 2020 4Q 2019 % Change Total Revenue $121.7 $53.7 127% Royalty Revenue $32.0 $17.2 86% Product Sales (incl. bulk rHuPH20 and ENHANZE® Drug Product Sales, and $32.5 $22.7 43% Hylenex® (Hyaluronidase Human Injection)) Collaborati

  9. Slide 9: Fourth Quarter 2020 Financial Highlights

    Fourth Quarter 2020 Financial Highlights1 $ U.S. in Millions, except EPS (unaudited) 4Q 2020 4Q 2019 % Change Total Revenue $121.7 $53.7 127% Total Operating Expense $44.1 $85.7 (49%) Cost of Product Sales $26.3 $16.7 57% R&D Expense $7.4 $45.1 (84%) SG&A Expense $10.4 $23.9 (56%) Operating Income $

  10. Slide 10: Full Year 2020 Financial Highlights

    Full Year 2020 Financial Highlights1 $ U.S. in Millions, except EPS (unaudited) FY 2020 FY 2019 % Change Royalties $88.6 $69.9 27% Product sales, net $56.0 $66.1 (15%) Collaboration Revenues $123.0 $60.0 105% Total Revenues $267.6 $196.0 37% Cost of product sales $43.4 $45.5 (5%) R&D $34.2 $140.8 --

  11. Slide 11: 2021 Financial Guidance

    2021 Financial Guidance 2021 Drivers • Growth of 40%-48% primarily driven by higher revenues from royalties • Revenues from royalties projected to double Net Revenue $375 - $395M • Product sales projected to increase 50-60% driven by bulk API orders • Revenues under collaborative agreements in a sim

  12. Slide 12: Potential Value-Driving Events in 2021

    Potential Value-Driving Events in 2021 Continued product launch momentum (Wave 2): • DARZALEX® SC: US and International. Potential Japan approval. Phesgo® US and EU Launch 4 products in Phase 3 in 7 Indications: Potential Wave 3 launches 5 NEW phase 1 starts resulting in 13 ongoing Phase 1: Potentia

  13. Slide 13: Fourth Quarter and Full Year 2020 Financial Results Presentation

    Fourth Quarter and Full Year 2020 Financial Results Presentation February 23, 2021 1 3

Halozyme Therapeutics — Q4 2020 Earnings Presentation on 6ix